eTheRNA Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Private

  • Employees
  • 118

Employees

  • Latest Deal Type
  • Series B2

  • Latest Deal Amount
  • $40.6M

  • Investors
  • 14

eTheRNA General Information

Description

Operator of a messenger ribonucleic acid technology development company intended to develop targeted and safe mRNA therapies for the human immune system. The company specializes in developing next-generation mRNA products that boost dendritic cells leading to a comprehensive, sustainable, and safe enhancement of the patient's immune system, enabling healthcare providers to assist patients in fighting cancer and other infectious diseases.

Contact Information

Website
www.etherna.be
Formerly Known As
eTheRNA Immunotherapies
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Galileilaan 19
  • 2845 Niel
  • Belgium
+32 03
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Other Devices and Supplies
Medical Supplies
Vertical(s)
Nanotechnology, Life Sciences, Oncology
Corporate Office
  • Galileilaan 19
  • 2845 Niel
  • Belgium
+32 03

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

eTheRNA Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC (Series B2) 23-Aug-2022 $40.6M Completed Generating Revenue
6. Later Stage VC (Series B) 16-Jun-2020 Completed Generating Revenue
5. Later Stage VC 25-Jul-2019 Completed Generating Revenue
4. Later Stage VC (Series A) 05-Jul-2018 Completed Generating Revenue
3. Grant 25-Sep-2017 Completed Generating Revenue
2. Accelerator/Incubator 05-Jan-2017 Completed Generating Revenue
1. University Spin-Out 01-Jan-2013 Completed Startup
To view eTheRNA’s complete valuation and funding history, request access »

eTheRNA Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Preference B2
Preference B2
Preference B2
Class B
Class B
Class B
Class B
Preference A
Preference 4,592 $2.45 $2.45 1x $2.45 0.31%
Preference 22,733 $1.43 $1.43 1x $1.43 1.54%
To view eTheRNA’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

eTheRNA Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a messenger ribonucleic acid technology development company intended to develop targeted and safe mRNA thera
Biotechnology
Niel, Belgium
118 As of 2025

Vancouver, Canada
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

eTheRNA Competitors (23)

One of eTheRNA’s 23 competitors is Precision Nanosystems, a Formerly VC-backed company based in Vancouver, Canada.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Precision Nanosystems Formerly VC-backed Vancouver, Canada
WaVe Life Sciences Formerly VC-backed Cambridge, MA
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom
CureVac Formerly VC-backed Tubingen, Germany
Kite Pharma Formerly VC-backed Santa Monica, CA
You’re viewing 5 of 23 competitors. Get the full list »

eTheRNA Patents

  • 63

    Total Documents Applications and Grants

  • Total Patents Families

  • 2

    Granted

  • 59

    Pending

  • Expiring in next 12 mo

eTheRNA Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023362573-A1 Ionizable lipids Pending 21-Oct-2022
EP-4526287-A1 Ionizable lipids Pending 20-May-2022
AU-2023269246-A1 A lyophilized rna composition Pending 12-May-2022
EP-4522114-A1 A lyophilized rna composition Pending 12-May-2022
EP-4518894-A1 Multi-epitope construct Pending 05-May-2022 A61K39/12
To view eTheRNA’s complete patent history, request access »

eTheRNA Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

eTheRNA Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds
Angel (individual) Minority
Wuhan Grand Pharmaceutical Corporation Minority
BNP Paribas Fortis Private Equity Growth/Expansion Minority
Grand Decade Corporation Minority
Novalis LifeSciences Venture Capital Minority
You’re viewing 5 of 14 investors. Get the full list »

eTheRNA Investments (2)

eTheRNA’s most recent deal was a Early Stage VC with Traianus Partners. The deal was made on 28-Mar-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Traianus Partners 28-Mar-2024 Early Stage VC Other Financial Services
AuroRNA Biotech 25-Nov-2020 Joint Venture Biotechnology
To view eTheRNA’s complete investments history, request access »

Ready to get started?

Request a free trial

eTheRNA FAQs

  • When was eTheRNA founded?

    eTheRNA was founded in 2013.

  • Where is eTheRNA headquartered?

    eTheRNA is headquartered in Niel, Belgium.

  • What is the size of eTheRNA?

    eTheRNA has 118 total employees.

  • What industry is eTheRNA in?

    eTheRNA’s primary industry is Biotechnology.

  • Is eTheRNA a private or public company?

    eTheRNA is a Private company.

  • What is the current valuation of eTheRNA?

    The current valuation of eTheRNA is .

  • What is eTheRNA’s current revenue?

    The current revenue for eTheRNA is .

  • How much funding has eTheRNA raised over time?

    eTheRNA has raised $122M.

  • Who are eTheRNA’s investors?

    , Wuhan Grand Pharmaceutical, BNP Paribas Fortis Private Equity, Grand Decade, and Novalis LifeSciences are 5 of 14 investors who have invested in eTheRNA.

  • Who are eTheRNA’s competitors?

    Precision Nanosystems, WaVe Life Sciences, Adaptimmune Therapeutics, CureVac, and Kite Pharma are some of the 23 competitors of eTheRNA.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »